• Daiichi Sankyo Q1 FY2026 revenue rose 21.1% year over year to JPY 574.7 billion, driven by oncology products.
• Operating profit fell 12.0% from a year earlier to JPY 85.1 billion, due to EU Specialty Business restructuring expenses.
• Enhertu revenue, including milestone payments, climbed 48.9% year over year to JPY 239.8 billion; Datroway more than doubled to JPY 23.9 billion.
• Management cited three new U.S. approvals for Enhertu and Datroway in a single week in May, supporting plans for 20-plus indications by 2030.
• FY2026 guidance was raised, with revenue seen at JPY 2.34 trillion and operating profit at JPY 320 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607310430BIZWIRE_USPR_____20260730_BW555689) on July 31, 2026, and is solely responsible for the information contained therein.